Legacy Specialty Pharmacy Flips to New Owners – BioMatrix
Earlier this week we sent a Report on Walmart opening twenty-five specialty pharmacies. That was about organic growth. Today we are reporting on the changing hands
Earlier this week we sent a Report on Walmart opening twenty-five specialty pharmacies. That was about organic growth. Today we are reporting on the changing hands
……….. catching up on FDA Approvals The FDA recently approved a new therapy, Ohtuvayre (ensifentrine) from Verona Pharma plc, for the maintenance treatment of chronic obstructive
……….catching up on FDA approvals We usually don’t report on expanded indications for a therapy previously approved by the FDA. This time one such approval
We’ve written about Value-Based Contracting (VBC) numerous times. The logic of VBC is self-evident. However, the feasibility and implementation of VBC is a totally different
The FDA recently approved a new infused therapy, Rytelo (imetelstat) from Geron Corporation, for the treatment of adult patients with low – to intermediate-1 risk
In the third century BCE a wonder of the world, the Colossus of Rhodes, stood as testament to ever lasting power and strength. As history tells,
………….. catching up on FDA Approvals The FDA recently approved a biosimilar….. meh news…… huh? But wait….. on the same day the FDA approved two biosimilars….. big news?
…….. catching up on FDA approvals The FDA recently approved a new infused therapy, Imdelltra (tarlatamab-dlle) from Amgen, indicated for the treatment of adult patients
The FDA recently approved a trastuzumab biosimilar, Hercessi (trastuzumab-strf; HLX02) from Accord BioPharma, to reference product Herceptin, for the treatment of several forms of HER2-positive
We just ran across an interesting article that spotlights four key takeaways from the Asembia Specialty Pharmacy Summit held earlier this year. Well, the article